Type 2 Diabetes Mellitus Trajectories and Associated Risks

被引:42
作者
Oh, Wonsuk [1 ]
Kim, Era [1 ]
Castro, M. Regina [3 ]
Caraballo, Pedro J. [4 ]
Kumar, Vipin [2 ]
Steinbach, Michael S. [2 ]
Simon, Gyorgy J. [1 ,5 ]
机构
[1] Univ Minnesota, Inst Hlth Informat, Minneapolis, MN USA
[2] Univ Minnesota, Dept Comp Sci & Engn, Minneapolis, MN USA
[3] Mayo Clin, Endocrinol Diabet Metab & Nutr, Rochester, MN 55905 USA
[4] Mayo Clin, Gen Internal Med, Rochester, MN 55905 USA
[5] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA
基金
美国国家科学基金会;
关键词
big data analytics; data mining; MODEL;
D O I
10.1089/big.2015.0029
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
Disease progression models, statistical models that assess a patient's risk of diabetes progression, are popular tools in clinical practice for prevention and management of chronic conditions. Most, if not all, models currently in use are based on gold standard clinical trial data. The relatively small sample size available from clinical trial limits these models only considering the patient's state at the time of the assessment and ignoring the trajectory, the sequence of events, that led up to the state. Recent advances in the adoption of electronic health record (EHR) systems and the large sample size they contain have paved the way to build disease progression models that can take trajectories into account, leading to increasingly accurate and personalized assessment. To address these problems, we present a novel method to observe trajectories directly. We demonstrate the effectiveness of the proposed method by studying type 2 diabetes mellitus (T2DM) trajectories. Specifically, using EHR data for a large population-based cohort, we identified a typical trajectory that most people follow, which is a sequence of diseases from hyperlipidemia (HLD) to hypertension (HTN), impaired fasting glucose (IFG), and T2DM. In addition, we also show that patients who follow different trajectories can face significantly increased or decreased risk.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 14 条
[1]   Executive Summary: Standards of Medical Care in Diabetes-2014 [J].
不详 .
DIABETES CARE, 2014, 37 :S5-S13
[2]  
[Anonymous], 2014, NAT DIAB STAT REP ES
[3]  
[Anonymous], 2012, DIAB REP CARD 2012 N
[4]   How Do We Define Cure of Diabetes? [J].
Buse, John B. ;
Caprio, Sonia ;
Cefalu, William T. ;
Ceriello, Antonio ;
Del Prato, Stefano ;
Inzucchi, Silvio E. ;
McLaughlin, Sue ;
Phillips, Gordon L., II ;
Robertson, R. Paul ;
Rubino, Francesco ;
Kahn, Richard ;
Kirkman, M. Sue .
DIABETES CARE, 2009, 32 (11) :2133-2135
[5]   A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) [J].
Clarke, PM ;
Gray, AM ;
Briggs, A ;
Farmer, AJ ;
Fenn, P ;
Stevens, RJ ;
Matthews, DR ;
Stratton, IM ;
Holman, RR .
DIABETOLOGIA, 2004, 47 (10) :1747-1759
[6]   Archimedes - A trial-validated model of diabetes [J].
Eddy, DM ;
Schlessinger, L .
DIABETES CARE, 2003, 26 (11) :3093-3101
[7]   MECHANISMS OF DIABETIC COMPLICATIONS [J].
Forbes, Josephine M. ;
Cooper, Mark E. .
PHYSIOLOGICAL REVIEWS, 2013, 93 (01) :137-188
[8]   Electronic Medical Records for Genetic Research: Results of the eMERGE Consortium [J].
Kho, Abel N. ;
Pacheco, Jennifer A. ;
Peissig, Peggy L. ;
Rasmussen, Luke ;
Newton, Katherine M. ;
Weston, Noah ;
Crane, Paul K. ;
Pathak, Jyotishman ;
Chute, Christopher G. ;
Bielinski, Suzette J. ;
Kullo, Iftikhar J. ;
Li, Rongling ;
Manolio, Teri A. ;
Chisholm, Rex L. ;
Denny, Joshua C. .
SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (79)
[9]  
Kim Era, 2014, AMIA Annu Symp Proc, V2014, P1815
[10]  
Knowler William C, 2002, N Engl J Med, V346, P393, DOI 10.1056/NEJMoa012512